Clinical trial
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
NCT00092027 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00092027 |
|---|---|
| Title | A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219) |
| Official title | A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | MK0217, alendronate sodium/Duration of Treatment: 6 months, Comparator: placebo / Duration of Treatment: 6 months |
| Enrollment | 454 |
| Start date | Mar 19, 2003 |
| Primary completion | Mar 15, 2004 |
| Completion | Mar 15, 2004 |
| First posted | Sep 24, 2004 |
| Last update posted | Aug 14, 2024 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: